• NEW! UVM Medical Center - Clinical Program Coordinator - Oncology CAR-T Therapy

• NEW! UVM Cancer Center - PhD Cancer Research, Scientist - Assistant Professor - Education Scholar Pathway

• NEW! UVM Medical Center/Larner College of Medicine  - GI Medical Oncology - Assistant Professor Clinician Scholar Pathway
• UVM Medical Center - Clinical Program Coordinator - Hematology 
• UVM Medical Center - CVMC - Medical Oncologist / Hematologist - general oncology and hematology (benign and malignant disease) and includes inpatient consult service and outpatient clinics 
• Northern Light Health - Physician Medical Director -Oncology Service Line
• UVM Cancer Center / Larner College of Medicine 
• Academic clinician with experience in lung cancer, melanoma and immunotherapy - Assistant or Associate Professor in the Clinical Scholars Pathway
• Physician-scientist/academic clinician with experience in breast cancer - Associate Professor or Full Professor in the Clinical Scholar Pathway
• Classical hematologist - Assistant Professor, Associate Professor, or Professor in the Clinical Scholar Pathway

Learn more about our unique funding program! 

POSTPONED - DATE TBD

Register for the series today and be sure to sign up for NNECOS sponsored lunch!

Join us in congratulating NAHPAC Special Award Recipients, Elizabeth McGrath and Nicole Messier! Saturday, September 10th, Nicole was recognized with a NAHPAC Distinguished Service Award, in recognition of her longstanding leadership as a co-chair of the committee, while Elizabeth was presented with a Founding Member Award, having served as a member of the committee since its founding in the fall of 2012. Thank you, Nicole and Elizabeth for your outstanding leadership and service to this important committee!

Please read this special message to our community.

Latest FDA Approvals

• January 27 - FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
• January 27 - FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma
• January 26 - FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
• January 19 - FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
• January 19 - FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma
• December 16 - FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer 
• December 14 - FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal
• December 12 - FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

Other Updates

ASCO Survey on COVID in Oncology Registry

The aim is to help the cancer community learn more about the patterns of symptoms & severity of COVID among patients with cancer, as well as the impact on delivery of cancer care & patient outcomes. Periodic reports will deliver real-time information to the oncology community.

• ASCO Registry FAQs
• Enroll Your Practice
• Questions

ASCO COVID Resource Page

COVID Info & Resources including a Fact Sheet on EUA of BAmlanivimab